Fulcrum Therapeutics, Inc. Common Stock
Here’s whether Fulcrum Therapeutics, Inc. Common Stock (FULC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.87% over 10 days); RSI 26 — oversold; weak 1-year return of -48.1%; 3-month momentum negative (-53.5%); rising volume on a downtrend (distribution, 2.40x avg). Currently 76.6% off its 52-week high. Score: -7/7.
FULC is trading below its 200-day MA ($8.73) — a key warning sign the longer-term trend is under pressure. An RSI of 25.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -48.1% compares to +24.4% for SPY (trailed the market by 72.5%). The current 76.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.